Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Supplemental Oxygen and Nitric Oxide Plus Oxygen for Pulmonary Vasoreactivity Testing
2004-000625-30Phase 3Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Sep 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of nitric oxide in pulmonary hypertension (PH) (3 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Pulmonary vasoreactivity with nitric oxide plus oxygen vs 100% oxygen. Started Sep 2004; status: completed.
02
Drugs
nitric oxide
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2004-000625-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000625-30.